Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
66
RVMD Quote, Financials, Valuation and Earnings
Last price:
$78.40
Seasonality move
:
-5.64%
Day range:
$76.53 - $79.06
52-week range:
$29.17 - $79.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.50x
Volume:
2.1M
Avg. volume:
2.3M
1-year change:
62.65%
Market cap:
$15.2B
Revenue:
--
EPS (TTM):
-$5.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RVMD
Revolution Medicines, Inc.
|
$1.5M | -$1.41 | -53.35% | -42.67% | $81.15 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$72.8M | -$0.26 | 11.66% | -35.2% | $8.25 |
|
IRON
Disc Medicine, Inc.
|
-- | -$1.46 | -- | -72.53% | $118.17 |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$4.2M | -$1.04 | -- | -18.07% | $31.00 |
|
TVTX
Travere Therapeutics, Inc.
|
$106.1M | -$0.09 | 91.27% | -87.94% | $41.5000 |
|
XBIO
Xenetic Biosciences, Inc.
|
$631.9K | -- | 6.75% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RVMD
Revolution Medicines, Inc.
|
$78.48 | $81.15 | $15.2B | -- | $0.00 | 0% | -- |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.20 | $8.25 | $873.3M | -- | $0.00 | 0% | 2.91x |
|
IRON
Disc Medicine, Inc.
|
$93.79 | $118.17 | $3.5B | -- | $0.00 | 0% | -- |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$16.40 | $31.00 | $829M | -- | $0.00 | 0% | 56.89x |
|
TVTX
Travere Therapeutics, Inc.
|
$35.3300 | $41.5000 | $3.2B | -- | $0.00 | 0% | 7.36x |
|
XBIO
Xenetic Biosciences, Inc.
|
$2.54 | -- | $5.8M | -- | $0.00 | 0% | 1.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RVMD
Revolution Medicines, Inc.
|
9.03% | 1.466 | 1.79% | 7.86x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.206 | 6.28% | 2.92x |
|
IRON
Disc Medicine, Inc.
|
5.13% | 1.216 | 1.34% | 23.03x |
|
KALV
KalVista Pharmaceuticals, Inc.
|
94.33% | -1.515 | 45.9% | 6.99x |
|
TVTX
Travere Therapeutics, Inc.
|
81.76% | 1.077 | 15.42% | 2.50x |
|
XBIO
Xenetic Biosciences, Inc.
|
-- | 3.604 | -- | 3.71x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RVMD
Revolution Medicines, Inc.
|
-$4.3M | -$315.3M | -47.95% | -51.27% | -- | -$210.7M |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
IRON
Disc Medicine, Inc.
|
-$87K | -$67.7M | -31.4% | -32.82% | -- | -$47.8M |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$12.5M | -$46.1M | -97.51% | -243.25% | -336.33% | -$54.8M |
|
TVTX
Travere Therapeutics, Inc.
|
$147.5M | $24.9M | -21.07% | -263.9% | 15.12% | -$871K |
|
XBIO
Xenetic Biosciences, Inc.
|
-- | -$544.7K | -59.39% | -59.39% | -53.04% | -$658.2K |
Revolution Medicines, Inc. vs. Competitors
-
Which has Higher Returns RVMD or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of -135.28%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital RVMDRevolution Medicines, Inc.-- -$1.61 $1.8B IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About RVMD or IOVA?
Revolution Medicines, Inc. has a consensus price target of $81.15, signalling upside risk potential of 3.4%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 275%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Revolution Medicines, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RVMDRevolution Medicines, Inc.17 0 0 IOVAIovance Biotherapeutics, Inc.6 4 1 -
Is RVMD or IOVA More Risky?
Revolution Medicines, Inc. has a beta of 0.959, which suggesting that the stock is 4.08% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.
-
Which is a Better Dividend Stock RVMD or IOVA?
Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RVMD or IOVA?
Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 2.91x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RVMDRevolution Medicines, Inc.-- -- -- -$305.2M IOVAIovance Biotherapeutics, Inc.2.91x -- $67.5M -$91.3M
-
Which has Higher Returns RVMD or IRON?
Disc Medicine, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of --. Revolution Medicines, Inc.'s return on equity of -51.27% beat Disc Medicine, Inc.'s return on equity of -32.82%.
Company Gross Margin Earnings Per Share Invested Capital RVMDRevolution Medicines, Inc.-- -$1.61 $1.8B IRONDisc Medicine, Inc.-- -$1.77 $604.4M -
What do Analysts Say About RVMD or IRON?
Revolution Medicines, Inc. has a consensus price target of $81.15, signalling upside risk potential of 3.4%. On the other hand Disc Medicine, Inc. has an analysts' consensus of $118.17 which suggests that it could grow by 25.99%. Given that Disc Medicine, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Disc Medicine, Inc. is more attractive than Revolution Medicines, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RVMDRevolution Medicines, Inc.17 0 0 IRONDisc Medicine, Inc.12 0 0 -
Is RVMD or IRON More Risky?
Revolution Medicines, Inc. has a beta of 0.959, which suggesting that the stock is 4.08% less volatile than S&P 500. In comparison Disc Medicine, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.406%.
-
Which is a Better Dividend Stock RVMD or IRON?
Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Disc Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Disc Medicine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RVMD or IRON?
Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Disc Medicine, Inc. quarterly revenues of --. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Disc Medicine, Inc.'s net income of -$62.3M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Disc Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus -- for Disc Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RVMDRevolution Medicines, Inc.-- -- -- -$305.2M IRONDisc Medicine, Inc.-- -- -- -$62.3M
-
Which has Higher Returns RVMD or KALV?
KalVista Pharmaceuticals, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of -361.39%. Revolution Medicines, Inc.'s return on equity of -51.27% beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.
Company Gross Margin Earnings Per Share Invested Capital RVMDRevolution Medicines, Inc.-- -$1.61 $1.8B KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M -
What do Analysts Say About RVMD or KALV?
Revolution Medicines, Inc. has a consensus price target of $81.15, signalling upside risk potential of 3.4%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 89.02%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Revolution Medicines, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RVMDRevolution Medicines, Inc.17 0 0 KALVKalVista Pharmaceuticals, Inc.7 0 0 -
Is RVMD or KALV More Risky?
Revolution Medicines, Inc. has a beta of 0.959, which suggesting that the stock is 4.08% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.
-
Which is a Better Dividend Stock RVMD or KALV?
Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RVMD or KALV?
Revolution Medicines, Inc. quarterly revenues are --, which are smaller than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. Revolution Medicines, Inc.'s net income of -$305.2M is lower than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 56.89x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RVMDRevolution Medicines, Inc.-- -- -- -$305.2M KALVKalVista Pharmaceuticals, Inc.56.89x -- $13.7M -$49.5M
-
Which has Higher Returns RVMD or TVTX?
Travere Therapeutics, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of 15.59%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.
Company Gross Margin Earnings Per Share Invested Capital RVMDRevolution Medicines, Inc.-- -$1.61 $1.8B TVTXTravere Therapeutics, Inc.89.46% $0.25 $403.3M -
What do Analysts Say About RVMD or TVTX?
Revolution Medicines, Inc. has a consensus price target of $81.15, signalling upside risk potential of 3.4%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 17.46%. Given that Travere Therapeutics, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Travere Therapeutics, Inc. is more attractive than Revolution Medicines, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RVMDRevolution Medicines, Inc.17 0 0 TVTXTravere Therapeutics, Inc.12 2 0 -
Is RVMD or TVTX More Risky?
Revolution Medicines, Inc. has a beta of 0.959, which suggesting that the stock is 4.08% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.
-
Which is a Better Dividend Stock RVMD or TVTX?
Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RVMD or TVTX?
Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 7.36x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RVMDRevolution Medicines, Inc.-- -- -- -$305.2M TVTXTravere Therapeutics, Inc.7.36x -- $164.9M $25.7M
-
Which has Higher Returns RVMD or XBIO?
Xenetic Biosciences, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of -49.65%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.
Company Gross Margin Earnings Per Share Invested Capital RVMDRevolution Medicines, Inc.-- -$1.61 $1.8B XBIOXenetic Biosciences, Inc.-- -$0.33 $4M -
What do Analysts Say About RVMD or XBIO?
Revolution Medicines, Inc. has a consensus price target of $81.15, signalling upside risk potential of 3.4%. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1474.8%. Given that Xenetic Biosciences, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Revolution Medicines, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RVMDRevolution Medicines, Inc.17 0 0 XBIOXenetic Biosciences, Inc.0 1 0 -
Is RVMD or XBIO More Risky?
Revolution Medicines, Inc. has a beta of 0.959, which suggesting that the stock is 4.08% less volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.
-
Which is a Better Dividend Stock RVMD or XBIO?
Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RVMD or XBIO?
Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Xenetic Biosciences, Inc. quarterly revenues of $1M. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 1.37x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RVMDRevolution Medicines, Inc.-- -- -- -$305.2M XBIOXenetic Biosciences, Inc.1.37x -- $1M -$509.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
